Novo Nordisk A/S
NVO
$65.77
$0.921.42%
NYSE
Recommendation
Prev Close
Volume
Avg Vol (90D)
Market Cap
Dividend & Yield
P/E (TTM)
EPS (TTM)
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 15.76% | 28.79% | 22.51% | 23.78% | 23.75% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 15.76% | 28.79% | 22.51% | 23.78% | 23.75% |
| Cost of Revenue | 25.94% | 24.80% | 17.47% | 29.15% | 22.47% |
| Gross Profit | 13.94% | 29.46% | 23.51% | 22.87% | 23.98% |
| SG&A Expenses | 8.30% | 7.77% | 18.95% | 3.09% | 8.03% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -102.39% | -137.08% | 203.99% | -2,766.30% | 1,839.38% |
| Total Operating Expenses | 13.63% | 15.42% | 18.89% | 18.28% | 19.38% |
| Operating Income | 18.01% | 45.90% | 26.81% | 30.78% | 28.69% |
| Income Before Tax | 12.40% | 27.44% | 23.63% | 3.14% | 30.39% |
| Income Tax Expenses | 19.02% | 28.22% | 27.97% | 8.08% | 33.65% |
| Earnings from Continuing Operations | 10.71% | 27.24% | 22.55% | 1.92% | 29.58% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 10.71% | 27.24% | 22.55% | 1.92% | 29.58% |
| EBIT | 18.01% | 45.90% | 26.81% | 30.78% | 28.69% |
| EBITDA | 21.43% | 44.43% | 23.30% | 31.77% | 28.57% |
| EPS Basic | 11.21% | 27.77% | 23.22% | 2.66% | 30.73% |
| Normalized Basic EPS | 12.91% | 38.60% | 24.33% | 27.29% | 31.55% |
| EPS Diluted | 11.38% | 27.85% | 23.50% | 2.65% | 30.75% |
| Normalized Diluted EPS | 13.02% | 38.69% | 24.41% | 27.40% | 31.62% |
| Average Basic Shares Outstanding | -0.45% | -0.41% | -0.55% | -0.73% | -0.88% |
| Average Diluted Shares Outstanding | -0.54% | -0.49% | -0.63% | -0.83% | -0.95% |
| Dividend Per Share | -- | 22.20% | -- | 15.22% | -- |
| Payout Ratio | 0.08% | -- | -0.04% | -- | 0.21% |